Integrating Assessment of Sarcopenia into Decision-making for Allogeneic Hematopoietic Cell Transplantation: Ready for Prime Time?
Menée à partir de données portant sur 859 patients atteints d'une leucémie aiguë ou d'un syndrome myélodysplasique et ayant reçu une greffe de cellules souches hématopoïétiques entre 2007 et 2014 (âge médian lors de la greffe : 51 ans), cette étude de cohorte rétrospective évalue l'association entre une sarcopénie mesurée avant la greffe et le risque de décès non lié à la récidive de la maladie dans les 2 ans suivant la greffe
The term sarcopenia, derived from the Greek words sarx meaning “flesh” and penia meaning “loss,” was initially utilized to describe age-associated muscle loss and function observed in the older population (1,2). Sarcopenia can occur in concert with biologic aging or can be secondary to inactivity or various disease processes such as chronic obstructive pulmonary disease, acquired immunodeficiency syndrome, or cancer (3). In 2010, a consensus definition of sarcopenia was developed by the European Working Group on Sarcopenia and Older People to include depletion in both muscle mass and muscle function, which was defined as reduced physical performance or muscle strength (4). The consensus noted that muscle strength can be preserved in those with reduced muscle mass and that the relationship between muscle mass and muscle function is not linear (1). The European consensus definition was updated in 2018 and places more emphasis on muscle strength over muscle mass citing reduced strength as a better predictor of adverse outcomes when compared to mass (5).
Journal of the National Cancer Institute , commentaire en libre accès, 2018